By Health Robotics today reported FY2013 new sales of 69 Robots [20 for Oncology, and 49 for non-hazardous IVs and TPNs] or 177% of FY2012 Robot Sales Units, plus 152 i.v.SOFT workflow software contracts or 217% of FY2012 i.v.SOFT Sales Units. Revenue Bookings rocketed to 232% of FY2012, making 2013 yet another record year for the undisputed global Sterile (IV) Compounding Automation leader.
For 4Q2013, Health Robotics reported 51 net new installations under contract, including 18 I.V. Robots (2 for Chemotherapy, and 16 for non-hazardous IVs and TPNs) and 33 i.v.SOFT workflow software agreements, now reaching 530 worldwide installations, http://www.health-robotics.com/en/installations/.
Gaspar DeViedma, Health Robotics' Executive Vice President, stated: "I'm very pleased with Health Robotics' record-breaking 2013 performance, which reflects a healthy mix of additional Robot and IV workflow software sales to its pre-existing customers, as well as sales to net new Health-System pharmacies. Of particular significance in 2013 was the overwhelming market acceptance of 2nd Generation i.v.STATION ONCO by Pharmacy Directors in the USA, Canada, Europe, and Australia, winning 100% of public tender decisions over its global competitors1."
During 4Q2013, Health Robotics and/or some of its global distributors signed 51 new purchase orders for: Albany Medical Center (NY), Duke University Cancer Center (NC), Fletcher Allen Health Care (VT), Maimonides Medical Center (NY), Penn Valley Forge (PA), Trinity Health-Saint Joseph Mercy (MI), SAHZ Haarlem (Netherlands), University of Maastricht (Netherlands), Hamad Medical (Qatar), and Süleymaniye Do?um ve Kad?n Hastanesi E?itim Ara? (Istanbul, Turkey).
Mr. DeViedma concluded: "i.v.STATION ONCO 2013's success undeniably validates Health Robotics' historical decision to divorce from Loccioni and the troubles caused by their old semi-automated robots that do not automatically cap nor auto-label chemotherapy doses. Many of Loccioni's APOTECAchemo issues were widely exposed2 for their ongoing problems at the November 15th edition of the American Journal of Health System Pharmacy2. Auspiciously, Health-System pharmacists continue to recognize the undeniable fact that Health Robotics' second generation modular architecture of integrated and networked medical devices are fully-automated, with automatic labeling and tamper-resistant capping, offering 3 to 4 times faster speed/throughput, for less than half the price, size, and weight than its major competitors2, while delivering payback periods/R.O.I. ranging from 6 months for i.v.STATION to 1.5 years for i.v.STATION ONCO."
About Health Robotics:
Founded in 2006, Health Robotics is the undisputed leading supplier of life-critical sterile compounding Robots with 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market]. Health Robotics provides more than 500 hospital installations in 5 continents with the only fully integrated, robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second-generation-platform products [i.v.STATION®, i.v.SOFT®, i.v.STATION® ONCO, and i.v.STATION® 2] have been found [through scientific and peer-reviewed studies3, 4, 5] to greatly contribute to ease hospitals' growing pressures to improve patient safety3, increase throughput3, and contain costs3. Through the effective and efficient production of sterile, accurate, tamper-evident, and ready-to-administer IVs and TPNs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug3 and diluent exchange errors, improve drug potency4, decrease other medical mistakes3 and sterility risks, work more efficiently3, reduce waste3 and controlled substances' diversion, decrease pharmacy technician upper-limb injuries5, and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff3.
For more information: http://www.health-robotics.com
1 Competitors: Intelligent Hospital Systems/RIVA, Fresenius
Kabi/MDS, Baxter/Baxa, and Loccioni.
2 Implementation
of an i.v.-compounding robot in a hospital-based cancer center pharmacy;
Am J Health Syst Pharm November 15, 2013 70:2030-2037
3 Impact
of Robotic Antineoplastic Preparation on Safety, Workflow, Costs.
Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick,
Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital,
Massachusetts College of Pharmacy, and Harvard Medical School. Journal
of Oncology Practice, Nov. 2012, Volume 8, number 6.
4 Validation
of an automated method for compounding monoclonal antibody patient
doses: case studies of Avastin®, Remicade®, and Herceptin®.
Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs
January 2013, Volume 5, Issue 1.
5 Comparing
the upper limb disorder risks associated with manual and automated
cytotoxic compounding. McLeod, Zochowska, Leonard, Crow, Jacklin,
Dean, Franklin. Imperial College Healthcare NHS Trust. European Journal
of Hospital Pharmacy April 2012.
Sarah Epstein, +1-786-417-1251
epstein@health-robotics.com
